Oppenheimer Raises Target on Alexion (ALXN) to $100 as Asfotase Alfa Data Looks Promising

March 29, 2012 3:33 PM EDT Send to a Friend
Get Alerts ALXN Hot Sheet
Price: $192.77 -0.71%

Rating Summary:
    13 Buy, 7 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 14 | New: 51
Trade ALXN Now!
Join SI Premium – FREE
Shares of recent momentum play Alexion Pharma (Nasdaq: ALXN) got a late-day boost Thursday after an intraday research note from Oppenheimer's Bret Holley. The analyst boosted his price target on Alexion shares from $89 to $100 and maintained an Outperform rating.

The report followed earlier results from Alexion's Phase 2 asfotase alfa study in adolescents and adults with HPP. Holley estimates the product could generate $1.1 billion in peak sales. He is expecting approval of asfotase alfa for infant and juvenile HPP during the second half of 2014 and approval for adults and adolescents shortly thereafter.

With Alexion shares up 0.95 percent to $91.07 at last check, the Oppenheimer analyst's new price target suggests potential upside of about 10 percent.

Visit our Analyst Ratings page to track all the market-moving analyst calls on shares of Alexion.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change

Add Your Comment